



Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73

U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

[Download now](#)

[Click here](#) if your download doesn't start automatically

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73

U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

Plasma-cell dyscrasias (PCDs) are a group of neoplastic disorders characterized by the uninhibited expansion of a monoclonal population of malignant plasma cells. Multiple myeloma (MM) is the most common malignant plasma-cell tumor, accounting for about 1 percent of all cancer types,¹ and the second most common hematologic malignancy in the United States. With an age-adjusted incidence rate of 5.5 cases per 100,000 population, an estimated 19,900 new diagnoses and 10,790 deaths due to myeloma occurred in 2007, according to the American Cancer Society. Although the median survival has improved to 5 years with current standards of treatment, the annual costs of modern therapies can range from \$50,000 to \$125,000 per patient. In PCDs, each abnormally expanded clone of malignant plasma cells produces an excess of either intact immunoglobulin or free light chains (FLCs) of a single type; either type of excess molecule is called a monoclonal protein (M protein) or paraprotein. Measurement of M proteins (either complete immunoglobulins or FLCs) is integral to diagnosing PCDs, monitoring disease response to therapy and adjusting treatment, and determining disease progression or relapse. The serum FLC (SFLC) assay (i.e., the Freelite® assay, The Binding Site Ltd., Birmingham, United Kingdom) was introduced in 2001 to measure the FLC component in serum. The assay works by recognizing an epitope that is detectable only on light chains that are not bound to the heavy chain of the immunoglobulin molecule—the FLCs—in the serum. This is the sole SFLC assay the U.S. Food and Drug Administration (FDA) has approved for use in the United States. The aim of this CER is to evaluate the present body of evidence addressing the relative effectiveness of the SFLC assay as compared with traditional tests for the diagnosis, management, and prognosis of PCDs. We sought to answer a set of questions focusing on the SFLC assay versus traditional testing in very specific clinical settings to focus on comparative effectiveness. Our goals were to evaluate the SFLC assay as an add-on test in diagnostic settings and to compare it with existing tests in other settings such as for disease monitoring and prognosis. Panels of Key Informants and Technical Experts, who helped identify the important areas for evidence review (as discussed in the Methods section), vetted these questions. To address these areas in an unbiased way that would permit summary of the relevant data, studies had to meet a specific, predefined set of criteria related to population, intervention (diagnostic test/disease monitoring), comparator, and outcome. This CER evaluates the SFLC assay as a diagnostic and prognostic tool adjunctive to the standard diagnostic tests for various PCDs. It addresses five Key Questions (KQs) that pertain to the (1) diagnosis of PCDs, (2) prognosis (i.e., progression from MGUS to MM and overall and disease-free survival in patients with a malignant PCD), (3) change in treatment decisions, (4) assessment of response to treatment, and (5) reduction of the need for other diagnostic tests (e.g., bone marrow biopsy).

 [Download Serum Free Light Chain Analysis for the Diagnosis, ...pdf](#)

 [Read Online Serum Free Light Chain Analysis for the Diagnosi ...pdf](#)

Download and Read Free Online Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality

From reader reviews:

Nicole Oneal:

Have you spare time for any day? What do you do when you have much more or little spare time? That's why, you can choose the suitable activity with regard to spend your time. Any person spent all their spare time to take a go walking, shopping, or went to typically the Mall. How about open or perhaps read a book entitled Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73? Maybe it is to get best activity for you. You recognize beside you can spend your time along with your favorite's book, you can more intelligent than before. Do you agree with its opinion or you have different opinion?

Dan Fry:

What do you concentrate on book? It is just for students because they're still students or it for all people in the world, exactly what the best subject for that? Merely you can be answered for that concern above. Every person has several personality and hobby for each other. Don't to be obligated someone or something that they don't want do that. You must know how great in addition to important the book Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73. All type of book are you able to see on many methods. You can look for the internet sources or other social media.

Daniel Bryant:

This Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 is great book for you because the content which is full of information for you who always deal with world and possess to make decision every minute. This specific book reveal it info accurately using great plan word or we can say no rambling sentences inside. So if you are read this hurriedly you can have whole information in it. Doesn't mean it only offers you straight forward sentences but challenging core information with beautiful delivering sentences. Having Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 in your hand like finding the world in your arm, facts in it is not ridiculous just one. We can say that no guide that offer you world in ten or fifteen tiny right but this e-book already do that. So , this can be good reading book. Hi Mr. and Mrs. stressful do you still doubt in which?

Juan Gilbert:

Do you like reading a book? Confuse to looking for your preferred book? Or your book had been rare? Why so many issue for the book? But virtually any people feel that they enjoy with regard to reading. Some people likes studying, not only science book but in addition novel and Serum Free Light Chain Analysis for

the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 or even others sources were given understanding for you. After you know how the fantastic a book, you feel wish to read more and more. Science publication was created for teacher or perhaps students especially. Those books are helping them to put their knowledge. In some other case, beside science guide, any other book likes Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 to make your spare time more colorful. Many types of book like this.

Download and Read Online Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality #K4MOTVDYCE7

Read Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality for online ebook

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality Free PDF d0wnl0ad, audio books, books to read, good books to read, cheap books, good books, online books, books online, book reviews epub, read books online, books to read online, online library, greatbooks to read, PDF best books to read, top books to read Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality books to read online.

Online Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality ebook PDF download

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality Doc

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality Mobipocket

Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Comparative Effectiveness Review Number 73 by U. S. Department of Health and Human Services, Agency for Healthcare Research and Quality EPub